182187-39-9

Usage

Uses

Used in Pharmaceutical Industry:
1-PHENYLSULFONYLINDOLE-5-METHANOL is used as a building block for the production of pharmaceuticals due to its unique structure and functional groups, which make it a versatile compound for use in chemical and pharmaceutical research.
Used in Organic Synthesis:
1-PHENYLSULFONYLINDOLE-5-METHANOL is used as a building block for the production of other organic compounds in organic synthesis, contributing to the development of new chemical entities and materials.

InChI:InChI=1/C15H13NO3S/c17-11-12-6-7-15-13(10-12)8-9-16(15)20(18,19)14-4-2-1-3-5-14/h1-10,17H,11H2

Upstream product

• 1670-81-1 1H-Indole-5-carboxylic acid 
• 98-09-9 benzenesulfonyl chloride 
• 1011-65-0 5-methoxycarbonylindole 

Downstream Products

• 1184953-71-6 5-(bromomethyl)-1-(phenylsulfonyl)-1H-indole 

Relevant academic research and scientific papers

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: Structure-based design and in vivo reduction of amyloid β-peptides

Structure-based design of a series of cyclic hydroxyethylamine BACE1 inhibitors allowed the rational incorporation of prime- and nonprime-side fragments to a central core template without any amide functionality. The core scaffold selection and the structure-activity relationship development were supported by molecular modeling studies and by X-ray analysis of BACE1 complexes with various ligands to expedite the optimization of the series. The direct extension from P1-aryl- and heteroaryl moieties into the S3 binding pocket allowed the enhancement of potency and selectivity over cathepsin D. Restraining the design and synthesis of compounds to a physicochemical property space consistent with central nervous system drugs led to inhibitors with improved blood-brain barrier permeability. Guided by structure-based optimization, we were able to obtain highly potent compounds such as 60p with enzymatic and cellular IC50 values of 2 and 50 nM, respectively, and with >200-fold selectivity over cathepsin D. Pharmacodynamic studies in APP51/16 transgenic mice at oral doses of 180 μmol/kg demonstrated significant reduction of brain Aβ levels.